Role of cholesterol in amyloid cascade: Cholesterol-dependent modulation of tau phosphorylation and mitochondrial function

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 185, 2006, Pages 21-26

  Michikawa, M ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Apolipoprotein E; Cholesterol; High density lipoprotein; Niemann Pick type C1 disease; Statin; Tau phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; STATINE DERIVATIVE; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENETIC RISK; HOMEOSTASIS; HUMAN; MEMBRANE STRUCTURE; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NIEMANN PICK DISEASE; PATHOGENESIS; PROTEIN LIPID INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TAUOPATHY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL TRANSPORT; CHOLESTEROL; HUMANS; MITOCHONDRIA; PHOSPHORYLATION; TAU PROTEINS;

EID: 33745758112     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00681.x     Document Type: Review

References (52)

1. ROHEIM PS, CAREY M, FORTE T, VEGA GL. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979;76:4646-9.
2. PITAS RE, BOYLES JK, LEE SH, HUI D, WEISGRABER KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-60.
3. LINTON MF, GISH R, HUBL ST et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991;88:270-81.
4. MAUCH DH, NAGLER K, SCHUMACHER S et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294:1354-7.
5. HAYASHI H, CAMPENOT RB, VANCE DE, VANCE JE. Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem 2004;279:14009-15.
6. SAITO M, BENSON EP, ROSENBERG A. Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture. J Neurosci Res 1987;18:319-25.
7. LADU MJ, GILLIGAN SM, LUKENS JR et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 1998;70:2070-81.
8. CRAIG AM, BANKER G. Neuronal polarity. Annu Rev Neurosci 1994;17:267-310.
9. OKABE S, KIM HD, MIWA A, KURIU T, OKADO H. Continual remodeling of postsynaptic density and its regulation by synaptic activity. Nat Neurosci 1999;2:804-11.
10. NOTKOLA IL, SULKAVA R, PEKKANEN J et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
11. KIVIPELTO M, HELKALA EL, HANNINEN T et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56:1683-989.
12. BOUTHILLIER D, SING CF, DAVIGNON J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res 1983;24:1060-9.
13. DAVIGNON J, GREGG RE, SING CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
14. LEHTINEN S, LEHTIMAKI T, SISTO T et al. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 1995;114:83-91.
15. BRAECKMAN L, DE BACQUER D, ROSSENEU M, DE BACKER G. Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis 1996;120:67-73.
16. FRIKKE-SCHMIDT R, NORDESTGAARD BG, AGERHOLM-LARSEN B, SCHNOHR P, TYBJAERG-HANSEN A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 2000;41:1812-22.
17. WOLOZIN B, KELLMAN W, RUOSSEAU P, CELESIA GG, SIEGEL G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
18. SIMONS M, KELLER P, DE STROOPER B, BEYREUTHER K, DOTTI CG, SIMONS K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95:6460-4.
19. FASSBENDER K, SIMONS M, BERGMANN C et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:5856-61.
20. MOLANDER-MELIN M, BLENNOW K, BOGDANOVIC N, DELLHEDEN B, MANSSON JE, FREDMAN P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005;92:171-82.
21. ABAD-RODRIGUEZ J, LEDESMA MD, CRAESSAERTS K et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004;167:953-60.
22. FAGAN AM, YOUNKIN LH, MORRIS JC et al. Differences in the A40/A42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000;48:201-10.
23. FASSBENDER K, STROICK M, BERTSCH T et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002;59:1257-8.
24. JUREVICS H, HOSTETTLER J, BARRETT C, MORELL P, TOEWS AD. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. J Lipid Res 2000;41:1048-54.
25. JARVIK GP, WIJSMAN EM, KUKULL WA, SCHELLENBERG GD, YU C, LARSON EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
26. EVANS RM, EMSLEY CL, GAO S et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000;54:240-2.
27. MICHIKAWA M, FAN QW, ISOBE I, YANAGISAWA K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 2000;74:1008-16.
28. GONG JS, KOBAYASHI M, HAYASHI H et al. Apolipoprotein E (apoE)-isoform-dependent lipid release from astrocytes prepared from human-apoE3- and apoE4-knock-in mice. J Biol Chem 2002;277:29919-26.
29. HOSHINO T, KAMINO K, MATSUMOTO M. Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging 2002;23:41-5.
30. MERCHED A, XIA Y, VISVIKIS S, SEROT JM, SIEST G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000;21:27-30.
31. MULDER M, RAVID R, SWAAB DF et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 1998;12:198-203.
32. ROHER AE, WEISS N, KOKJOHN TA et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002;41:11080-90.
33. WALSH DM, KLYUBIN I, FADEEVA JV, ROWAN MJ, SELKOE DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002;30:552-7.
34. MICHIKAWA M, GONG JS, FAN QW, SAWAMURA N, YANAGISAWA K. A novel action of Alzheimer's amyloid b-protein (Ab): oligomeric Ab promotes lipid release. J Neurosci 2001;21:7226-35.
35. GONG JS, SAWAMURA N, ZOU K, SAKAI J, YANAGISAWA K, MICHIKAWA M. Amyloid β-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 2002;70:438-46.
36. ZOU K, GONG JS, YANAGISAWA K, MICHIKAWA M. A novel function of monomeric amyloid β-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002;22:4833-4841.
37. FAN QW, YU W, GONG JS et al. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem 2002;80:178-90.
38. KOUDINOV AR, KOUDINOVA NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. Faseb J 2001;15:1858-60.
39. FAN QW, WEI Y, SENDA T, YANAGISAWA K, MICHIKAWA M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 2001;76:391-400.
40. SAWAMURA N, GONG JS, CHANG TY, YANAGISAWA K, MICHIKAWA M. Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. J Neurochem 2003;84:1086-96.
41. SAWAMURA N, KO M, YU W et al. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem 2004;279:11984-91.
42. SUZUKI K, PARKER CC, PENTCHEV PG et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol (Berl) 1995;89:227-38.
43. AUER IA, SCHMIDT ML, LEE VM et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol (Berl) 1995;90:547-51.
44. LOVE S, BRIDGES LR, CASE CP. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995;118(Pt 1): 119-29.
45. SAWAMURA N, GONG JS, GARVER WS et al. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 2001;276:10314-9.
46. BU B, LI J, DAVIES P, VINCENT I. Deregulation of cdk5: hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 2002;22:6515-25.
47. YU W, GONG JS, KO M, GARVER WS, YANAGISAWA K, MICHIKAWA M. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J Biol Chem 2005;280:11731-9.
48. HIRAI K, ALIEV G, NUNOMURA A et al. Mitochondrial bnormalities in Alzheimer's disease. J Neurosci 2001;21:3017-23.
49. CARDOSO SM, PROENCA MT, SANTOS S, SANTANA I, OLIVEIRA CR. Cytochrome C oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 2004;25:105-10.
50. ABRAMOV AY, CANEVARI L, DUCHEN MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24:565-75.
51. MICHIKAWA M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 2003;72:141-6.
52. MICHIKAWA M, YANAGISAWA K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 1999;72:2278-85.